Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTRON vs DEGARELIX ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.
Mild to moderate pain,Fever
Treatment of advanced prostate cancer
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 43-73 days after subcutaneous administration, reflecting slow release from the depot formulation.
Primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9), sulfation (SULT1A1, SULT1A3), and oxidation (CYP2E1, CYP3A4) to form the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Hepatic via hydrolysis of the acetate ester; no significant CYP450 involvement.
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
Renal elimination accounts for approximately 20-30% of the dose as unchanged drug; fecal elimination accounts for 70-80% primarily as metabolites.
>99% bound to albumin.
Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
0.1-0.2 L/kg; indicates limited extravascular distribution.
Approximately 1 L/kg, indicating extensive distribution into tissues.
Oral: 70-90% (first-pass metabolism minimal); IV: 100%.
Subcutaneous: approximately 100% for the depot formulation; not available orally due to peptide degradation.
GFR <30 m L/min: Avoid use. GFR 30-50 m L/min: Reduce dose to 50% of normal, maximum 600 mg/day.
No dose adjustment required for GFR ≥15 m L/min. Insufficient data for GFR <15 m L/min or dialysis; use caution.
Child-Pugh Class B: Reduce dose by 50%; maximum 600 mg/day. Child-Pugh Class C: Contraindicated.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
Children ≥12 years: 400 mg orally every 6-8 hours as needed; maximum 1200 mg/day. Children <12 years: Not recommended.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Initiate at 200 mg every 6-8 hours; maximum 600 mg/day due to increased risk of gastrointestinal bleeding and renal impairment.
No specific dose adjustment required; similar efficacy and safety observed in elderly patients (≥65 years) compared to younger adults.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Most cases involve use of acetaminophen at doses exceeding 4000 mg per day, often involving more than one acetaminophen-containing product.
None
Hepatotoxicity: risk increased with chronic alcohol use, liver disease, or use of other acetaminophen-containing products. Avoid exceeding 4000 mg/day. Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis. Hypersensitivity reactions: anaphylaxis.
Hypersensitivity reactions including anaphylaxis and angioedema,QT interval prolongation,Laboratory test interference with gonadotropin and gonadal steroid assays,Injection site reactions including pain and erythema,Bone density loss,Hyperglycemia and increased risk of diabetes
Severe hepatic impairment or active liver disease. Known hypersensitivity to acetaminophen or any component of the formulation.
Hypersensitivity to degarelix or any component of the formulation,Pregnancy (potential fetal harm)
Avoid alcohol; may increase risk of GI bleeding. No specific food restrictions, but taking with food can reduce gastrointestinal irritation. Maintain adequate hydration to prevent renal impairment.
No specific food interactions have been identified. Degarelix is administered parenterally and does not interact with dietary components. Avoid grapefruit juice if concurrent QT-prolonging drugs are used, but not a direct interaction with degarelix.
First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closure of ductus arteriosus and oligohydramnios with prolonged use. Avoid after 30 weeks gestation.
Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential for fetal androgen deprivation leading to ambiguous genitalia in male fetuses.
Excreted in breast milk; M/P ratio 0.15. Low oral bioavailability to infant; considered compatible with breastfeeding. Monitor infant for sedation or feeding problems.
No data available on excretion in human milk; potential for serious adverse effects in nursing infants; discontinue breastfeeding or discontinue drug.
Dose adjustment not typically required; however, due to increased renal clearance and volume of distribution in pregnancy, higher doses may be needed to achieve therapeutic effect. Use lowest effective dose for shortest duration.
No dose adjustments are applicable as degarelix is contraindicated in pregnancy; therapy must be discontinued if pregnancy occurs.
ACTRON (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) for short-term management of moderate to severe acute pain, typically not exceeding 5 days due to risk of GI bleeding, renal impairment, and cardiovascular events. Avoid in patients with active peptic ulcer disease, bleeding diathesis, or advanced renal disease. Monitor renal function and signs of bleeding. Use lowest effective dose for shortest duration. May cause bronchospasm in aspirin-sensitive asthma.
Degarelix acetate is a Gn RH antagonist used for advanced prostate cancer. It provides rapid testosterone suppression without the initial testosterone surge seen with Gn RH agonists. Monitor serum testosterone and PSA levels; castrate levels (<50 ng/d L) typically achieved within 3 days. Injection site reactions are common; rotate injection sites (abdomen, thigh, buttock). Avoid in patients with known QT prolongation or concurrent QT-prolonging drugs. Contraindicated in women and children.
Take with food or milk to reduce stomach upset.,Do not take for more than 5 days as prescribed; longer use increases risk of serious side effects.,Avoid alcohol while taking this medication to lower risk of stomach bleeding.,Report any signs of bleeding (e.g., black stools, vomiting blood), unusual bruising, or decreased urination.,Do not take with other NSAIDs (e.g., ibuprofen, naproxen) or aspirin without consulting your doctor.,Inform your doctor about all medications, especially blood thinners (e.g., warfarin) and diuretics.,If you have asthma, be aware of potential bronchospasm; seek immediate help if you have breathing trouble.,Not recommended during pregnancy, especially in the third trimester.
Degarelix is given as a subcutaneous injection by a healthcare provider every month (or every 2 months for maintenance dose) to treat advanced prostate cancer.,Do not miss scheduled injections because consistent dosing is needed to keep testosterone levels low.,Common side effects include injection site pain, redness, or swelling; hot flashes; increased liver enzymes; and weight gain.,Report signs of allergic reaction (rash, itching, difficulty breathing) or prolonged QT interval (fainting, palpitations) to your doctor immediately.,Degarelix may cause bone thinning; discuss calcium and vitamin D supplementation with your doctor.,This drug can cause harm to a fetus; not for use in women or children.
No interactions on record
"Asenapine, a second-generation antipsychotic, is associated with dose-dependent QTc interval prolongation due to its inhibitory effects on cardiac potassium channels (specifically IKr). Degarelix, a GnRH antagonist used in prostate cancer, may also cause QTc prolongation, likely through hormonal suppression mechanisms. Coadministration can result in additive QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with pre-existing risk factors."
"Dolasetron, a 5-HT3 receptor antagonist, is known to cause dose-dependent prolongation of the QT interval by blocking cardiac potassium channels. When coadministered with Degarelix, a GnRH receptor antagonist that also reduces testosterone levels and can induce QT prolongation via electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) or direct cardiac effects, the risk of additive QT prolongation is increased. This may lead to a higher propensity for torsade de pointes and other ventricular arrhythmias, particularly in patients with pre-existing risk factors."
"Cabazitaxel is a taxane antineoplastic agent that undergoes extensive hepatic metabolism via CYP3A4/5 and is a substrate of P-glycoprotein. Degarelix, a GnRH antagonist, has no known direct metabolic interaction with Cabazitaxel but may theoretically increase the risk of QT prolongation when combined with other drugs. However, the baseline description is vague; the interaction is not well-established and possibly refers to additive myelosuppression or cardiovascular effects from overlapping toxicities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTRON vs DEGARELIX ACETATE, answered by our medical review team.
ACTRON is a NSAID that works by Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.. DEGARELIX ACETATE is a GnRH antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTRON and DEGARELIX ACETATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTRON is: Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.. The standard adult dose of DEGARELIX ACETATE is: Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTRON and DEGARELIX ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTRON is classified as Category C. First trimester: Based on animal studies and limited human data, possible increased risk of cardiovascular and neural tube defects. Second/third trimester: Risk of premature closur. DEGARELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.